Background: Curcumin, an active ingredient of the Indian herb turmeric (Curcuma longa), has shown promising anti-inflammatory properties. Studies of its potential benefits in treating patients with ulcerative colitis (UC) are limited. We performed a systematic review and meta-analysis of human randomized placebo controlled trials to evaluate the efficacy of adjunctive therapy with curcumin in treating patients with UC.
Methods: We conducted a search of several databases (from January 2000 to September 2018). A random-effects model was used for analysis. We assessed heterogeneity between study-specific estimates using the Cochran Q statistical test, 95% prediction interval (PI) and I2 statistics. The outcomes assessed were the pooled odds of clinical response and remission as well as the endoscopic response.
Results: A total of 7 studies with 380 patients (curcumin n=188; placebo n=190) were included in the final analysis. The pooled odds ratio for clinical remission with curcumin use was 2.9 (95%CI 1.5-5.5, I2=45, P=0.002), clinical response was 2.6 (95%CI 1.5-4.5, I2=74%, P=0.001), and endoscopic response/remission was 2.3 (95%CI 1.2-4.6, I2=35.5%, P=0.01).
Conclusions: Based on our study, combined mesalamine and curcumin therapy was associated with roughly threefold better odds of a clinical response compared to placebo, with minimal side effects. This response was statistically significant, albeit with heterogeneity, probably due to the different severity scoring indices, curcumin dosages and routes of drug delivery used.
Keywords: Ulcerative colitis; curcumin; meta-analysis.
Copyright: © Hellenic Society of Gastroenterology.
Conflict of interest statement
Conflict of Interest: None
Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysisU Iqbal et al. Am J Med Sci 356 (4), 350-356. PMID 30360803. - Meta-AnalysisThis study demonstrates higher clinical remission rates when curcumin was used in combination with mesalamine to achieve remission in patients with UC. Curcumin, due to i …
Curcumin for Maintenance of Remission in Ulcerative ColitisS Kumar et al. Cochrane Database Syst Rev 10, CD008424. PMID 23076948. - ReviewCurcumin may be a safe and effective therapy for maintenance of remission in quiescent UC when given as adjunctive therapy along with mesalamine or sulfasalazine. However …
Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: An Evidence-based Clinical ReviewM Simadibrata et al. Acta Med Indones 49 (4), 363-368. PMID 29348389. - ReviewAvailable evidence showed that curcumin has the potential to induce and maintain remission in UC patients with no serious side effects. However, further studies with larg …
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled TrialA Lang et al. Clin Gastroenterol Hepatol 13 (8), 1444-9.e1. PMID 25724700. - Randomized Controlled TrialAddition of curcumin to mesalamine therapy was superior to the combination of placebo and mesalamine in inducing clinical and endoscopic remission in patients with mild-t …
Efficacy of Adjuvant Curcumin Therapy in Ulcerative Colitis: A Meta-Analysis of Randomized Controlled TrialsT Zheng et al. J Gastroenterol Hepatol. PMID 31696975.Curcumin, as an adjuvant treatment of mesalamine, was proved to be effective and safe in ulcerative colitis. Better efficacy can be achieved with suitable dose, delivery …
- Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol. 1991;26:1247–1256. - PubMed
- Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis:a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260–266. - PubMed
- Panahi Y, Khalili N, Sahebi E, et al. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus:a randomized double-blind placebo-controlled trial. Drug Res (Stuttg) 2018;68:403–409. - PubMed
- Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease:a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68:223–229. - PubMed